Wenxue Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenxue Gao has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Ran Cui
Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China
5 shared publications Fang Yin
Shanghai Engineering Research Center of Human Intestinal Microflora Function Development, Shanghai Tenth People's Hospital, Shanghai 200072, China
2 shared publications- Yinghua Li
Department of Orthopedics, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China; Shanghai Clinical Research Center for Aging and Medicine, Shanghai, China; Center of Community-Based Health Research, Fudan University, Shanghai, China
2 shared publications - Zhaoliang Fei
Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publications - Bin Su
Department of Transfusion, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Bin Su
Department of Blood Transfusion, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 25 May 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-14
The diabetic neuropathy and bone mineral density in type 2 diabetes mellitus: a cross-sectional and meta-analytic study
Diabetic neuropathy (DN) is a common complication of type 2 diabetes mellitus (T2DM), yet its impact on bone mineral density (BMD) remains unclear. This study combines cross-sectional and meta-analytic methods to comprehensively explore the relationship between DN and osteoporosis in T2DM patients. The cross-sectional study included 523 T2DM patients, classified into DN and non-DN groups. BMD was measured using dual-energy X-ray absorptiometry (DXA), and multivariate analysis identified osteoporosis-related factors. The meta-analysis included studies published from 1999 to 2021, comparing BMD between patients with and without DN. The results showed that while significant differences in clinical characteristics and biochemical indices (such as age, HbA1c, and 25(OH) vitamin D levels) were observed between the groups, no significant association between DN and osteoporosis was found after adjusting for covariates like body mass index and blood pressure. Additionally, the meta-analysis confirmed no significant impact of DN on BMD across skeletal sites, including the lumbar spine, hip, and femoral neck. These findings suggest that while DN may indirectly affect bone health through alterations in bone metabolism (such as bone formation markers), its direct impact on BMD is limited. The study's limitations include its cross-sectional design, which restricts causal inference, and retrospective data collection, underscoring the need for prospective studies to further elucidate the mechanisms behind DN’s effects on bone health. These results highlight the complex interplay of factors influencing osteoporosis risk in T2DM and underscore the importance of a multifactorial approach to bone health management in this population.
- 25 May 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-14
Open AccessThe diabetic neuropathy and bone mineral density in type 2 diabetes mellitus: a cross-sectional and meta-analytic study
Diabetic neuropathy (DN) is a common complication of type 2 diabetes mellitus (T2DM), yet its impact on bone mineral density (BMD) remains unclear. This study combines cross-sectional and meta-analytic methods to comprehensively explore the relationship between DN and osteoporosis in T2DM patients. The cross-sectional study included 523 T2DM patients, classified into DN and non-DN groups. BMD was measured using dual-energy X-ray absorptiometry (DXA), and multivariate analysis identified osteoporosis-related factors. The meta-analysis included studies published from 1999 to 2021, comparing BMD between patients with and without DN. The results showed that while significant differences in clinical characteristics and biochemical indices (such as age, HbA1c, and 25(OH) vitamin D levels) were observed between the groups, no significant association between DN and osteoporosis was found after adjusting for covariates like body mass index and blood pressure. Additionally, the meta-analysis confirmed no significant impact of DN on BMD across skeletal sites, including the lumbar spine, hip, and femoral neck. These findings suggest that while DN may indirectly affect bone health through alterations in bone metabolism (such as bone formation markers), its direct impact on BMD is limited. The study's limitations include its cross-sectional design, which restricts causal inference, and retrospective data collection, underscoring the need for prospective studies to further elucidate the mechanisms behind DN’s effects on bone health. These results highlight the complex interplay of factors influencing osteoporosis risk in T2DM and underscore the importance of a multifactorial approach to bone health management in this population.
- 4 March 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (4) , 707-714
Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients
Summary This study examined the link between baseline CTX levels and zoledronic acid’s effectiveness in boosting bone density in osteoporosis patients. Among 472 Chinese patients, higher initial CTX levels correlated with greater lumbar spine bone density improvement after treatment. However, no such correlation was found for hip or femoral neck bones. This suggests CTX levels may aid in treatment selection for lumbar spine, though further research is needed. The findings have clinical implications for optimizing osteoporosis treatment. Purpose To elucidate the correlation between baseline CTX levels and the therapeutic efficacy of zoledronic acid in augmenting bone mineral density (BMD) among individuals with osteoporosis. Methods This study studied patients diagnosed with primary osteoporosis who were hospitalized at least twice and received annual zoledronic acid therapy. Patients were stratified into three groups based on their initial CTX levels prior to zoledronic acid administration. ANOVA was employed to compare BMD alterations across the groups. Generalized estimating equations (GEE) were utilized to analyze the relationship between baseline CTX levels and subsequent BMD changes post-zoledronic acid treatment. Statistical analyses were conducted using SPSS version 26.0. Results A total of 472 patients were evaluated and categorized into three cohorts according to their initial CTX levels, arranged in ascending order. Notably, group 3, characterized by the highest initial CTX levels, demonstrated a significantly more pronounced increase in lumbar spine BMD compared to the other two groups. Specifically, when group 1 served as the reference, group 3 exhibited a 0.4-unit elevation in lumbar spine T-score. Conversely, no discernible relationship was observed between baseline CTX levels and BMD changes in the hip or femoral neck following zoledronic acid treatment. Conclusions Our findings among a Chinese population indicate that elevated CTX levels, particularly exceeding 0.480 ng/ml, are notably associated with enhanced therapeutic efficacy of zoledronic acid in boosting lumbar spine BMD. However, this correlation appears less robust with respect to improvements in hip and femoral neck BMD.
- 4 March 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (4) , 707-714
Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients
Summary This study examined the link between baseline CTX levels and zoledronic acid’s effectiveness in boosting bone density in osteoporosis patients. Among 472 Chinese patients, higher initial CTX levels correlated with greater lumbar spine bone density improvement after treatment. However, no such correlation was found for hip or femoral neck bones. This suggests CTX levels may aid in treatment selection for lumbar spine, though further research is needed. The findings have clinical implications for optimizing osteoporosis treatment. Purpose To elucidate the correlation between baseline CTX levels and the therapeutic efficacy of zoledronic acid in augmenting bone mineral density (BMD) among individuals with osteoporosis. Methods This study studied patients diagnosed with primary osteoporosis who were hospitalized at least twice and received annual zoledronic acid therapy. Patients were stratified into three groups based on their initial CTX levels prior to zoledronic acid administration. ANOVA was employed to compare BMD alterations across the groups. Generalized estimating equations (GEE) were utilized to analyze the relationship between baseline CTX levels and subsequent BMD changes post-zoledronic acid treatment. Statistical analyses were conducted using SPSS version 26.0. Results A total of 472 patients were evaluated and categorized into three cohorts according to their initial CTX levels, arranged in ascending order. Notably, group 3, characterized by the highest initial CTX levels, demonstrated a significantly more pronounced increase in lumbar spine BMD compared to the other two groups. Specifically, when group 1 served as the reference, group 3 exhibited a 0.4-unit elevation in lumbar spine T-score. Conversely, no discernible relationship was observed between baseline CTX levels and BMD changes in the hip or femoral neck following zoledronic acid treatment. Conclusions Our findings among a Chinese population indicate that elevated CTX levels, particularly exceeding 0.480 ng/ml, are notably associated with enhanced therapeutic efficacy of zoledronic acid in boosting lumbar spine BMD. However, this correlation appears less robust with respect to improvements in hip and femoral neck BMD.
- Open Access
- 22 December 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 212, 65-79
SOD3 regulates FLT1 to affect bone metabolism by promoting osteogenesis and inhibiting adipogenesis through PI3K/AKT and MAPK pathways
- 22 December 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 212, 65-79
Open AccessSOD3 regulates FLT1 to affect bone metabolism by promoting osteogenesis and inhibiting adipogenesis through PI3K/AKT and MAPK pathways
- Open Access
- 24 October 2022
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 10, 1026924
Manganese-based Prussian blue nanoparticles inhibit tumor proliferation and migration via the MAPK pathway in pancreatic cancer
Pancreatic cancer (PC) is one of the deadliest gastrointestinal malignancies. Advances in molecular biology and surgery have significantly improved survival rates for other tumors in recent decades, but clinical outcomes for PC remained relatively unchanged. Chemodynamic therapy (CDT) and Photothermal therapy (PTT) represent an efficient and relatively safe cancer treatment modality. Here, we synthesized Mn-doped Prussian blue nanoparticles (MnPB NPs) through a simple and mild method, which have a high loading capacity for drugs and excellent CDT/PTT effect. Cell line experiments in vitro and animal experiments in vivo proved the safety of MnPB NPs. We stimulated the PC cells with MnPB NPs and performed transwell migration assays. The migration of PC cells was reduced company with the decrease of two classical proteins: matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Moreover, MnPB NPs induced ferroptosis, which mediated the MAPK pathway and achieved tumor elimination in nude mice. This effective and safe strategy controlled by irradiation represents a promising strategy for pancreatic cancer.
- 24 October 2022
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 10, 1026924
Open AccessManganese-based Prussian blue nanoparticles inhibit tumor proliferation and migration via the MAPK pathway in pancreatic cancer
Pancreatic cancer (PC) is one of the deadliest gastrointestinal malignancies. Advances in molecular biology and surgery have significantly improved survival rates for other tumors in recent decades, but clinical outcomes for PC remained relatively unchanged. Chemodynamic therapy (CDT) and Photothermal therapy (PTT) represent an efficient and relatively safe cancer treatment modality. Here, we synthesized Mn-doped Prussian blue nanoparticles (MnPB NPs) through a simple and mild method, which have a high loading capacity for drugs and excellent CDT/PTT effect. Cell line experiments in vitro and animal experiments in vivo proved the safety of MnPB NPs. We stimulated the PC cells with MnPB NPs and performed transwell migration assays. The migration of PC cells was reduced company with the decrease of two classical proteins: matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Moreover, MnPB NPs induced ferroptosis, which mediated the MAPK pathway and achieved tumor elimination in nude mice. This effective and safe strategy controlled by irradiation represents a promising strategy for pancreatic cancer.
- 2 February 2022
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 40 (3) , 460-467
Sexual dimorphism in the relation between sex hormones and osteoporosis in patients with type 2 diabetes mellitus
Introduction To investigate the association between sex hormones and osteoporosis in type 2 diabetic mellitus (T2DM) patients. Materials and methods We performed a retrospective study in patients with T2DM. The patients were assigned into three groups (normal bone mineral density, osteopenia, and osteoporosis) in both sexes. The clinical characteristics, bone metabolic markers, and sex hormones were compared. The relationship between the sex hormones and osteoporosis was analyzed by ordinary regression analysis. Statistical analysis was performed using SPSS 26.0. Results A total of 795 T2DM patients (446 men ≥ 50 years old and 349 postmenopausal women) were identified and analyzed. The osteoporosis group had the lowest estradiol level in men (P = 0.013) and the highest follicle-stimulating hormone (FSH) level in women (P = 0.042). In the multivariate analysis, men with lower estradiol levels (< 87.96 pmol/L) had a nearly 1.6-fold increased risk for osteoporosis than those with the higher estradiol levels (> 122.82 pmol/L). In addition, women with lower FSH (< 41.17 IU/L) had nearly 0.6-fold for osteoporosis compared to those with higher FSH (> 60.83 IU/L) after adjusting for age, duration of T2DM, body mass index, pulse pressure, creatinine clearance, glycosylated hemoglobin, fasting C-peptide, and estradiol (in FSH) or FSH (in estradiol). Conclusion In T2DM, the estrogen level was negatively correlated with osteoporosis in men, and the FSH level was positively correlated with the osteoporosis in women.
- 2 February 2022
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 40 (3) , 460-467
Sexual dimorphism in the relation between sex hormones and osteoporosis in patients with type 2 diabetes mellitus
Introduction To investigate the association between sex hormones and osteoporosis in type 2 diabetic mellitus (T2DM) patients. Materials and methods We performed a retrospective study in patients with T2DM. The patients were assigned into three groups (normal bone mineral density, osteopenia, and osteoporosis) in both sexes. The clinical characteristics, bone metabolic markers, and sex hormones were compared. The relationship between the sex hormones and osteoporosis was analyzed by ordinary regression analysis. Statistical analysis was performed using SPSS 26.0. Results A total of 795 T2DM patients (446 men ≥ 50 years old and 349 postmenopausal women) were identified and analyzed. The osteoporosis group had the lowest estradiol level in men (P = 0.013) and the highest follicle-stimulating hormone (FSH) level in women (P = 0.042). In the multivariate analysis, men with lower estradiol levels (< 87.96 pmol/L) had a nearly 1.6-fold increased risk for osteoporosis than those with the higher estradiol levels (> 122.82 pmol/L). In addition, women with lower FSH (< 41.17 IU/L) had nearly 0.6-fold for osteoporosis compared to those with higher FSH (> 60.83 IU/L) after adjusting for age, duration of T2DM, body mass index, pulse pressure, creatinine clearance, glycosylated hemoglobin, fasting C-peptide, and estradiol (in FSH) or FSH (in estradiol). Conclusion In T2DM, the estrogen level was negatively correlated with osteoporosis in men, and the FSH level was positively correlated with the osteoporosis in women.
- 30 October 2021
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 16 (1) , 1-8
Anemia is related to osteoporosis in Chinese type 2 diabetic patients
Summary Both anemia and osteoporosis are common in type 2 diabetes mellitus (T2DM). However, the relationship between them remains to be determined. This study showed that anemia was related to osteoporosis in male and female T2DM patients. Diabetes patients with anemia should also be wary of osteoporosis. Introduction Anemia and osteoporosis are considered complications of type 2 diabetes mellitus (T2DM). However, the relationship between anemia and osteoporosis in the T2DM population remains to be determined. Thus, we planned the present study to verify their relationship. Methods A retrospective cross-sectional study was performed. The patients were divided into groups according to sex and hemoglobin levels (Q1: ≤ 120, Q2: 120 to ≤ 140, Q3: > 140 in men; Q1: ≤ 110, Q2: 110 to ≤ 130, Q3: > 130 in women). Clinical characteristics and bone mineral density (BMD) were compared. The relationship between anemia and osteoporosis was determined after adjusting for age, diabetic duration, body mass index, alanine aminotransferase, creatinine, HbA1c, and fasting C-peptide. Statistical analysis was performed using SPSS 26.0. Results This study included 2336 patients (1150 men and 1186 postmenopausal women). The percentage of osteoporosis differed by hemoglobin status in both men (Q1: 20.2%, Q2: 15.5%, Q3: 12.4%, P = 0.031) and women (Q1: 51.4%, Q2: 38.0%, Q3: 34.5%, P < 0.001). Q1, with the lowest hemoglobin level, has higher percentage of osteoporosis in men (20.2%) and in women (51.4%). Hip BMD (men: r = 0.168, P < 0.001, women: r = 0.126, P < 0.001) and femur neck BMD (men: r = 0.150, P < 0.001, women: r = 0.134, P < 0.001) were correlated with hemoglobin levels in both sexes. The odds of osteoporosis increased 1.4-fold in men and 2.0-fold in women in the Q1 groups compared with Q3 groups. Conclusion Anemia was related to osteoporosis in T2DM patients regardless of sex. Diabetic patients with anemia (men with hemoglobin below 120 g/L and women with hemoglobin below 110 g/L) should also be wary of osteoporosis.
- 30 October 2021
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 16 (1) , 1-8
Anemia is related to osteoporosis in Chinese type 2 diabetic patients
Summary Both anemia and osteoporosis are common in type 2 diabetes mellitus (T2DM). However, the relationship between them remains to be determined. This study showed that anemia was related to osteoporosis in male and female T2DM patients. Diabetes patients with anemia should also be wary of osteoporosis. Introduction Anemia and osteoporosis are considered complications of type 2 diabetes mellitus (T2DM). However, the relationship between anemia and osteoporosis in the T2DM population remains to be determined. Thus, we planned the present study to verify their relationship. Methods A retrospective cross-sectional study was performed. The patients were divided into groups according to sex and hemoglobin levels (Q1: ≤ 120, Q2: 120 to ≤ 140, Q3: > 140 in men; Q1: ≤ 110, Q2: 110 to ≤ 130, Q3: > 130 in women). Clinical characteristics and bone mineral density (BMD) were compared. The relationship between anemia and osteoporosis was determined after adjusting for age, diabetic duration, body mass index, alanine aminotransferase, creatinine, HbA1c, and fasting C-peptide. Statistical analysis was performed using SPSS 26.0. Results This study included 2336 patients (1150 men and 1186 postmenopausal women). The percentage of osteoporosis differed by hemoglobin status in both men (Q1: 20.2%, Q2: 15.5%, Q3: 12.4%, P = 0.031) and women (Q1: 51.4%, Q2: 38.0%, Q3: 34.5%, P < 0.001). Q1, with the lowest hemoglobin level, has higher percentage of osteoporosis in men (20.2%) and in women (51.4%). Hip BMD (men: r = 0.168, P < 0.001, women: r = 0.126, P < 0.001) and femur neck BMD (men: r = 0.150, P < 0.001, women: r = 0.134, P < 0.001) were correlated with hemoglobin levels in both sexes. The odds of osteoporosis increased 1.4-fold in men and 2.0-fold in women in the Q1 groups compared with Q3 groups. Conclusion Anemia was related to osteoporosis in T2DM patients regardless of sex. Diabetic patients with anemia (men with hemoglobin below 120 g/L and women with hemoglobin below 110 g/L) should also be wary of osteoporosis.